Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of silmitasertib in combination with chemotherapy * Test the safety and tolerability of silmitasertib

Trial Details

NCT ID
NCT06541262
Phase
PHASE1 / PHASE2
Sponsor
Milton S. Hershey Medical Center
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Silmitasertib
  • Irinotecan
  • Temozolomide
  • Vincristine
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Oakland, California, United States|37.80437,-122.2708
  • Sacramento, California, United States|38.58157,-121.4944
  • San Diego, California, United States|32.71571,-117.16472

Key Eligibility Criteria

  • Age: Less than 30 years old at initial diagnosis
  • Pathology All subjects must have a confirmed diagnosis of tumor type. Phase I: Relapsed/refractory solid tumors: Neuroblastoma, Ewing Sarcoma, Oste…
  • Relapsed/refractory Neuroblastoma
  • Relapsed/refractory Ewing sarcoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →